Implantable cardioverter-defibrillator (ICD) therapy has expanded significantly for primary and secondary prevention of sudden cardiac death, improving survival compared with antiarrhythmic drugs.
implanted the first implantable cardioverter-defibrillator (ICD) in a young female with recurrent ventricular fibrillation and provided an innovative approach to aborted sudden cardiac death (SCD). Although the ICD was considered a treatment of last resort during that incipient stage, subsequent years have witnessed prolific expansion of indications for ICD implantation. 2 Several large-scale clinical trials have demonstrated its efficacy for both primary and secondary prevention of SCD in patients with ischemic and nonischemic cardiomyopathy. 3,4 ICD therapy in such high-risk patients has been shown to improve survival compared with conventional antiarrhythmic drug therapy alone. 3,4 The number of ICD implantations has increased significantly in the last decade, with a concurrent decrease in the use of stand-alone antiarrhythmic drugs for ventricular indications. 5 ]7 Current ICDs have sophisticated programming capabilities, atrial and bipolar leads, and are able to deliver antitachycardia pacing algorithms (ATP) in addition to defibrillating shocks.
Patel et al. (Tue,) conducted a review in Sudden cardiac death and recurrent ventricular fibrillation. Catheter Ablation / Implantable cardioverter-defibrillator (ICD) vs. Antiarrhythmic drug therapy was evaluated. Implantable cardioverter-defibrillator (ICD) therapy has expanded significantly for primary and secondary prevention of sudden cardiac death, improving survival compared with antiarrhythmic drugs.